{"name":"Camurus","slug":"camurus","ticker":"CAMX.ST","exchange":"NASDAQ Stockholm","domain":"camurus.com","description":"Camurus AB (publ) is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.","hq":"Lund, Sweden","founded":2008,"employees":"285","ceo":"Fredrik Tiberg, PhD","sector":"Specialty Pharma / Drug Delivery","stockPrice":494.6,"stockChange":22.6,"stockChangePercent":4.79,"marketCap":"$29.6B","metrics":{"revenue":2265378048,"revenueGrowth":-16,"grossMargin":93.1,"rdSpend":0,"netIncome":735568000,"cash":3725967104,"dividendYield":0,"peRatio":40.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Buvidal patent cliff ($1.2B at risk)","drug":"Buvidal","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Camban patent cliff ($500M at risk)","drug":"Camban","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lanreotide ATG","genericName":"Lanreotide ATG","slug":"lanreotide-atg","indication":"Acromegaly","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAM2029","genericName":"CAM2029","slug":"cam2029","indication":"Opioid use disorder (maintenance treatment)","status":"phase_3"}]}],"pipeline":[{"name":"Lanreotide ATG","genericName":"Lanreotide ATG","slug":"lanreotide-atg","phase":"phase_3","mechanism":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","indications":["Acromegaly","Neuroendocrine tumors (carcinoid syndrome)","Gastroenteropancreatic neuroendocrine tumors"],"catalyst":""},{"name":"CAM2029","genericName":"CAM2029","slug":"cam2029","phase":"phase_3","mechanism":"CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment.","indications":["Opioid use disorder (maintenance treatment)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Camurus reports Q4 2023 results","summary":"Camurus reported its Q4 2023 results, with revenue of SEK 1.3 billion and a net loss of SEK 1.1 billion.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Camurus partners with Mundipharma for buprenorphine implant","summary":"Camurus has partnered with Mundipharma to commercialize its buprenorphine implant, Buvidal, in several countries.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"FDA approves Camurus' fentanyl implant","summary":"The FDA has approved Camurus' fentanyl implant, Camban, for the treatment of breakthrough pain in patients with cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-18","type":"pipeline","source":"simplywall.st","summary":"These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts - simplywall.st","headline":"These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-13","type":"pipeline","source":"simplywall.st","summary":"Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress - simplywall.st","headline":"Why Camurus (OM:CAMX) Is Down 24.8% After Lifting 2026 Guidance and Showcasing Oxyesa Progress","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"pipeline","source":"simplywall.st","summary":"Declining Stock and Solid Fundamentals: Is The Market Wrong About Camurus AB (publ) (STO:CAMX)? - simplywall.st","headline":"Declining Stock and Solid Fundamentals: Is The Market Wrong About Camurus AB (publ) (STO:CAMX)?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-09","type":"earnings","source":"simplywall.st","summary":"Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss - simplywall.st","headline":"Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOLUpwbmMzS21adDluMUFfTWo3X3lzYmprV2pFTDFNeUlabGlKbnVxR010aUhGY1Qtdnltcno1blExWG04M1F1a0lNWFlLeUFOOTFnMnluTnROUnVjN2NjNG51QXk2Q0tzQWZ1OG91VEpDNVJfdlFjYXhiY0tLTFYwN25FLVNxLTI1Z1ZrenNJa0VJYkNjVFM3bXBsdjA1dzVzaldQRzhlZzVfVlQ0NzNIQ3RuMDZnallBYy1STHlubTlCcXlmMUpNdGJR?oc=5","date":"2024-10-22","type":"regulatory","source":"reuters.com","summary":"US FDA declines to approve Camurus' rare hormone disorder drug - reuters.com","headline":"US FDA declines to approve Camurus' rare hormone disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNLXdFM0xsX08ySHh5QmE2M2Q4TlR3cUtma1kyWEZkY3RwdGFhdVNUaXpJWHRJZjk5R3BnSzdxdndYaU9kUXNmZ25wVlVjV00wLWh1STJmUXlIQ2dXNU5DWElzY090c1NHOWxCOHRtUEZHYUhGZG1mVmpLc3hFV1pxN2xlUGhyXzhrMi05TVdVNnJIcXpXUTNsZURjWXdHSjVhc2xvTmJ4U2w4QW1sako3S0xFaGVOaEpOWVllZ2Q1dG5BUEF5YTkwcFI5N01PekNXSWUw?oc=5","date":"2024-10-10","type":"earnings","source":"reuters.com","summary":"Indivior's opioid treatment sales slump prompts second profit warning - reuters.com","headline":"Indivior's opioid treatment sales slump prompts second profit warning","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9OTkZPRGozZEItUUh0TEg3MXpHd2c1czBKcTdDNUliWHU1Y21zbkl5T0FZQkg4SVBWaExHNWpudFljUDM2RHc4Q0tYU093RjF4RFRIcUNR?oc=5","date":"2017-06-10","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Camurus AB (publ) (CAMX.ST) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Camurus AB (publ) (CAMX.ST) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Buvidal","drugSlug":"buprenorphine","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Camban","drugSlug":"fentanyl","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":500000000}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Aquestive Therapeutics","Pfizer","Johnson & Johnson"],"therapeuticFocus":["Pain management","Addiction treatment"],"financials":null,"yahoo":{"currentPrice":494.6,"previousClose":472,"fiftyTwoWeekHigh":754.5,"fiftyTwoWeekLow":430.8,"fiftyTwoWeekRange":"430.8 - 754.5","fiftyDayAverage":532.17,"twoHundredDayAverage":625.74,"beta":0.45,"enterpriseValue":24530229248,"forwardPE":32.1,"priceToBook":6.96,"priceToSales":13.05,"enterpriseToRevenue":10.83,"enterpriseToEbitda":27.29,"pegRatio":0,"ebitda":898934016,"ebitdaMargin":39.7,"freeCashflow":329232256,"operatingCashflow":869302016,"totalDebt":106030000,"debtToEquity":2.5,"currentRatio":12.09,"returnOnAssets":12.9,"returnOnEquity":19.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":7,"targetMeanPrice":768,"targetHighPrice":930,"targetLowPrice":610,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":36.3,"institutionHeldPercent":36.2,"sharesOutstanding":59749184,"floatShares":36734775,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":12.28,"epsForward":15.39,"revenuePerShare":38.24,"bookValue":71.02,"officers":[{"age":62,"name":"Mr. Fredrik  Tiberg","title":"President, CEO, CSO & Director"},{"age":56,"name":"Mr. Anders Fink Vadsholt M.B.A., M.Sc.","title":"Chief Financial Officer"},{"age":57,"name":"Ms. Susanne  Lagerlund","title":"Vice President of Technical Operations"},{"age":67,"name":"Mr. Rein  Piir B.Sc.","title":"Vice President of Investor Relations"},{"age":50,"name":"Bo A. C. TarrasWahlberg","title":"VP of Legal & Group General Counsel"},{"age":50,"name":"Ms. Jane Buus Laursen Ph.D.","title":"Chief Corporate Development Officer"},{"age":59,"name":"Ms. Maria  Lundqvist","title":"Global Head of Human Resources"},{"age":53,"name":"Mr. Markus  Johnsson","title":"Senior Vice President of R&D"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.camurus.com","phone":"46 4 62 86 57 30"}}